Literature DB >> 19860649

"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.

Balveen Kaur1, Timothy P Cripe, E Antonio Chiocca.   

Abstract

Oncolytic viral therapy is a promising biological therapy for the treatment of cancer. Recent advances in genetic engineering have facilitated the construction of custom-built oncolytic viruses that can be exquisitely targeted to tumors by exploiting each cancer's unique biology and their efficacy can be further enhanced by "arming" them with additional therapeutic genes. Such an approach allows the virus to unload its "therapeutic cargo" at the tumor site, thereby enhancing its anti-neoplastic properties. While several clever strategies have been recently described using genes that can induce cellular apoptosis/suicide and/or facilitate tumor/virus imaging, viruses armed with genes that also affect the tumor microenvironment present an exciting and promising approach to therapy. In this review we discuss recently developed oncolytic viruses armed with genes encoding for angiostatic factors, inflammatory cytokines, or proteases that modulate the extracellular matrix to regulate tumor vascularization, anti-tumor immune responses and viral spread throughout the solid tumor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19860649      PMCID: PMC2802461          DOI: 10.2174/156652309789753329

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  152 in total

1.  Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.

Authors:  K Ikeda; H Wakimoto; T Ichikawa; S Jhung; F H Hochberg; D N Louis; E A Chiocca
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.

Authors:  J N Parker; G Y Gillespie; C E Love; S Randall; R J Whitley; J M Markert
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

3.  Gene therapy of experimental brain tumors using neural progenitor cells.

Authors:  S Benedetti; B Pirola; B Pollo; L Magrassi; M G Bruzzone; D Rigamonti; R Galli; S Selleri; F Di Meco; C De Fraja; A Vescovi; E Cattaneo; G Finocchiaro
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

4.  Local endostatin treatment of gliomas administered by microencapsulated producer cells.

Authors:  T A Read; D R Sorensen; R Mahesparan; P O Enger; R Timpl; B R Olsen; M H Hjelstuen; O Haraldseth; R Bjerkvig
Journal:  Nat Biotechnol       Date:  2001-01       Impact factor: 54.908

5.  Continuous release of endostatin from microencapsulated engineered cells for tumor therapy.

Authors:  T Joki; M Machluf; A Atala; J Zhu; N T Seyfried; I F Dunn; T Abe; R S Carroll; P M Black
Journal:  Nat Biotechnol       Date:  2001-01       Impact factor: 54.908

6.  Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.

Authors:  K M Giezeman-Smits; H Okada; C S Brissette-Storkus; L A Villa; J Attanucci; M T Lotze; I F Pollack; M E Bozik; W H Chambers
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

7.  Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy.

Authors:  N Kuriyama; H Kuriyama; C M Julin; K Lamborn; M A Israel
Journal:  Hum Gene Ther       Date:  2000-11-01       Impact factor: 5.695

8.  Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.

Authors:  Ta-Chiang Liu; Pedro Castelo-Branco; Samuel D Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2008-04-01       Impact factor: 11.454

9.  Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition.

Authors:  J Y Yoo; J-H Kim; J Kim; J-H Huang; S N Zhang; Y-A Kang; H Kim; C-O Yun
Journal:  Gene Ther       Date:  2008-02-14       Impact factor: 5.250

10.  Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus.

Authors:  Yoon-A Kang; Hyun-Chul Shin; Ji Young Yoo; Joo-Hang Kim; Jin-Soo Kim; Chae-Ok Yun
Journal:  Mol Ther       Date:  2008-04-08       Impact factor: 11.454

View more
  31 in total

Review 1.  Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?

Authors:  Ryuichi Kanai; Hiroaki Wakimoto; Tooba Cheema; Samuel D Rabkin
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma.

Authors:  Amy Haseley; Sean Boone; Jeffrey Wojton; Lianbo Yu; Ji Young Yoo; Jianhua Yu; Kazuhiko Kurozumi; Joseph C Glorioso; Michael A Caligiuri; Balveen Kaur
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

Review 3.  Thunder and lightning: immunotherapy and oncolytic viruses collide.

Authors:  Alan Melcher; Kelley Parato; Cliona M Rooney; John C Bell
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

4.  Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.

Authors:  Fang Wang; Zhiping Wang; Hongwei Tian; Meijiao Qi; Zhenxing Zhai; Shuwen Li; Renju Li; Hongjuan Zhang; Wenyun Wang; Shenjun Fu; Jianzhong Lu; Ronald Rodriguez; Yinglu Guo; Liqun Zhou
Journal:  Curr Gene Ther       Date:  2012-04-01       Impact factor: 4.391

Review 5.  Oncolytic viruses and their application to cancer immunotherapy.

Authors:  E Antonio Chiocca; Samuel D Rabkin
Journal:  Cancer Immunol Res       Date:  2014-04       Impact factor: 11.151

6.  A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.

Authors:  Jean-Simon Diallo; Fabrice Le Boeuf; Frances Lai; Julie Cox; Markus Vaha-Koskela; Hesham Abdelbary; Heather MacTavish; Katherine Waite; Theresa Falls; Jenny Wang; Ryan Brown; Jan E Blanchard; Eric D Brown; David H Kirn; John Hiscott; Harry Atkins; Brian D Lichty; John C Bell
Journal:  Mol Ther       Date:  2010-04-13       Impact factor: 11.454

7.  Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus.

Authors:  Ji Young Yoo; Amy Haseley; Anna Bratasz; E Antonio Chiocca; Jianying Zhang; Kimerly Powell; Balveen Kaur
Journal:  Mol Ther       Date:  2011-10-25       Impact factor: 11.454

Review 8.  Impact of tumor microenvironment on oncolytic viral therapy.

Authors:  Jeffrey Wojton; Balveen Kaur
Journal:  Cytokine Growth Factor Rev       Date:  2010 Apr-Jun       Impact factor: 7.638

Review 9.  Anti-angiogenic gene therapy in the treatment of malignant gliomas.

Authors:  NaTosha N Gatson; E Antonio Chiocca; Balveen Kaur
Journal:  Neurosci Lett       Date:  2012-08-10       Impact factor: 3.046

Review 10.  Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.

Authors:  Ryuichi Kanai; Samuel D Rabkin
Journal:  CNS Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.